Ultragenyx Pharmaceutical (RARE) Equity Ratio: 2016-2025
Historic Equity Ratio for Ultragenyx Pharmaceutical (RARE) over the last 10 years, with Sep 2025 value amounting to 0.01.
- Ultragenyx Pharmaceutical's Equity Ratio fell 96.59% to 0.01 in Q3 2025 from the same period last year, while for Sep 2025 it was 0.01, marking a year-over-year decrease of 96.59%. This contributed to the annual value of 0.17 for FY2024, which is 8.07% down from last year.
- As of Q3 2025, Ultragenyx Pharmaceutical's Equity Ratio stood at 0.01, which was down 93.36% from 0.12 recorded in Q2 2025.
- In the past 5 years, Ultragenyx Pharmaceutical's Equity Ratio ranged from a high of 0.66 in Q1 2021 and a low of 0.01 during Q3 2025.
- Moreover, its 3-year median value for Equity Ratio was 0.12 (2025), whereas its average is 0.13.
- Per our database at Business Quant, Ultragenyx Pharmaceutical's Equity Ratio skyrocketed by 780.18% in 2024 and then tumbled by 96.59% in 2025.
- Ultragenyx Pharmaceutical's Equity Ratio (Quarterly) stood at 0.61 in 2021, then tumbled by 62.36% to 0.23 in 2022, then fell by 19.01% to 0.18 in 2023, then declined by 8.07% to 0.17 in 2024, then crashed by 96.59% to 0.01 in 2025.
- Its last three reported values are 0.01 in Q3 2025, 0.12 for Q2 2025, and 0.11 during Q1 2025.